Frequent genomic alterations and better prognosis among young patients with non-small-cell lung cancer aged 40 years or younger
ConclusionsYoung patients are associated with an increased likelihood of gene mutations and can receive a better prognosis when patients harboring gene mutations are treated with EGFR-TKIs or ALK inhibitors.
Source: Clinical and Translational Oncology - Category: Cancer & Oncology Source Type: research
More News: Adenocarcinoma | Brain | Brain Cancers | Cancer | Cancer & Oncology | Carcinoma | Chemotherapy | Genetics | Lung Cancer | Lymphoma | Neurology | Non-Small Cell Lung Cancer | Skin Cancer | Smokers | Squamous Cell Carcinoma